5.6.2026 – UMBI Research Updates Series (RUS) in Molecular Medicine

 

5 June 2026 | This morning’s ๐”๐Œ๐๐ˆ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐”๐ฉ๐๐š๐ญ๐ž ๐’๐ž๐ซ๐ข๐ž๐ฌ ๐ข๐ง ๐Œ๐จ๐ฅ๐ž๐œ๐ฎ๐ฅ๐š๐ซ ๐Œ๐ž๐๐ข๐œ๐ข๐ง๐ž ๐๐จ. ๐Ÿ๐Ÿ’/๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” featured an insightful presentation by ๐”๐Œ๐๐ˆ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐…๐ž๐ฅ๐ฅ๐จ๐ฐ, ๐ƒ๐ซ. ๐’๐ข๐ญ๐ข ๐€๐ข๐ฌ๐ก๐š๐ก ๐’๐ฎ๐ฅ๐š๐ข๐ฆ๐š๐ง, entitled โ€œFatty Liver: Thin Doesn’t Mean Immuneโ€.

The session highlighted fatty liver disease as a growing global health concern and a silent epidemic, with prevalence continuing to rise worldwide. Dr. Aishah shared that the global prevalence reached approximately 38% in 2022, affecting an estimated 3 billion individuals, while more than 30% of the population in South-East Asia is affected. In Malaysia, findings from the ๐๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐‡๐ž๐š๐ฅ๐ญ๐ก ๐š๐ง๐ ๐Œ๐จ๐ซ๐›๐ข๐๐ข๐ญ๐ฒ ๐’๐ฎ๐ซ๐ฏ๐ž๐ฒ (๐๐‡๐Œ๐’) ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ‘ indicate that approximately 28% of Malaysians have fatty liver disease.
A key focus of the presentation was the often-overlooked phenomenon of Lean MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), where ๐ข๐ง๐๐ข๐ฏ๐ข๐๐ฎ๐š๐ฅ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐š ๐ง๐จ๐ซ๐ฆ๐š๐ฅ ๐›๐จ๐๐ฒ ๐ฆ๐š๐ฌ๐ฌ ๐ข๐ง๐๐ž๐ฑ (๐๐Œ๐ˆ) ๐ฆ๐š๐ฒ ๐ฌ๐ญ๐ข๐ฅ๐ฅ ๐๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ ๐Ÿ๐š๐ญ๐ญ๐ฒ ๐ฅ๐ข๐ฏ๐ž๐ซ. The audience was introduced to the concept of ๐“๐Ž๐…๐ˆ (๐“๐ก๐ข๐ง ๐Ž๐ฎ๐ญ๐ฌ๐ข๐๐ž, ๐…๐š๐ญ ๐ˆ๐ง๐ฌ๐ข๐๐ž), describing individuals with relatively low subcutaneous fat but high levels of visceral fat, which may increase MASLD risk despite appearing lean. Dr. Aishah also discussed the ๐ฉ๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐ซ๐จ๐ฅ๐ž ๐จ๐Ÿ ๐ญ๐ก๐ž ๐๐๐๐‹๐€๐Ÿ‘๐ˆ๐Ÿ๐Ÿ’๐Ÿ–๐Œ ๐ ๐ž๐ง๐ž๐ญ๐ข๐œ ๐ฏ๐š๐ซ๐ข๐š๐ง๐ญ ๐ข๐ง ๐‹๐ž๐š๐ง ๐Œ๐€๐’๐‹๐ƒ ๐ฌ๐ฎ๐ฌ๐œ๐ž๐ฉ๐ญ๐ข๐›๐ข๐ฅ๐ข๐ญ๐ฒ.

The presentation further explored the differences between obese and lean MASLD profiles, highlighting current clinical challenges and the tendency for ๐‹๐ž๐š๐ง ๐Œ๐€๐’๐‹๐ƒ ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ ๐ญ๐จ ๐›๐ž ๐ฎ๐ง๐๐ž๐ซ-๐ฌ๐œ๐ซ๐ž๐ž๐ง๐ž๐ ๐๐ฎ๐ž ๐ญ๐จ ๐ฉ๐ซ๐ž๐ฏ๐š๐ข๐ฅ๐ข๐ง๐  ๐œ๐ฅ๐ข๐ง๐ข๐œ๐š๐ฅ ๐›๐ข๐š๐ฌ ๐ญ๐ก๐š๐ญ ๐š๐ฌ๐ฌ๐จ๐œ๐ข๐š๐ญ๐ž๐ฌ ๐Ÿ๐š๐ญ๐ญ๐ฒ ๐ฅ๐ข๐ฏ๐ž๐ซ ๐ฉ๐ซ๐ข๐ฆ๐š๐ซ๐ข๐ฅ๐ฒ ๐ฐ๐ข๐ญ๐ก ๐จ๐›๐ž๐ฌ๐ข๐ญ๐ฒ.

The session concluded with an engaging Q&A discussion, reflecting strong interest from participants. Appreciation is extended to Dr. Aishah for her informative sharing and to all attendees for their active participation and insightful questions.

Pautan berita Facebook UMBI
Pautan berita LinkedIn UMBI


SDG 4 – Quality Education